Latest Mitochondrial disease Stories

MOUNTAIN VIEW, Calif., March 28, 2013 /PRNewswire/ -- Edison Pharmaceuticals today announced that it has entered into a research/development and commercialization agreement with Dainippon Sumitomo Pharma Co., Ltd. (DSP) for the development of EPI-743 and EPI-589 in Japan. Under the terms of the agreement, DSP will gain development and commercialization rights in Japan in exchange for Edison receiving $35 million in upfront and $15 million in R&D support. In addition, Edison will...

In an ongoing effort to improve mitochondrial disease patient care, MitoAction, in collaboration with the organization’s Medical Advisory Committee, will host the 2013 Mitochondrial Disease Clincial Conference on May 4, 2013 at Hotel Marlowe in Cambridge, MA. (PRWEB) March 20, 2013 In an ongoing effort to improve mitochondrial disease patient care, MitoAction, in collaboration with the organization’s Medical Advisory Committee, will host the 2013 Mitochondrial Disease Clincial...

Researchers at the University of Granada have produced for the first time in the world mice lacking the coenzyme Q10, a rare mitochondrial disease prevailingly affecting children. The researchers needed three years to complete the study. At three to six months of life, this genetic alteration in mice –similar to that occurred in human– causes a rapid degeneration in the lower limbs to death for cardiac arrest. For the first time in the world, researchers at the Center for Biomedical...

--CHOP Researchers' New Single-Platform Tool Streamlines Diagnoses of Complicated Multisystem Disorders-- PHILADELPHIA, Jan. 29, 2013 /PRNewswire-USNewswire/ -- More powerful gene-sequencing tools have increasingly been uncovering disease secrets in DNA within the cell nucleus. Now a research team is expanding those rapid next-generation sequencing tests to analyze a separate source of DNA--within the genes inside mitochondria, cellular power plants that, when abnormal, contribute to...

MOUNTAIN VIEW, Calif., Jan. 7, 2013 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "Safety and Efficacy Study of EPI-743 on Visual Function in Patients with Friedreich's Ataxia." The trial is a placebo-controlled study lasting six months, followed by an extension phase in which all subjects will receive EPI-743. Subjects must be between 18 and 45 years of age, possess genetic confirmation of Friedreich's ataxia, and meet...

Connie K. Ho for redOrbit.com – Your Universe Online Researchers from the Columbia University Medical Center (CUMC) and the New York Stem Cell Foundation (NYSCF) have been able to create a new technique that limits inherited disorders in children. The ability of scientists to transfer the nucleus of a cell from one human egg cell to another was considered an important achievement, and results of the study were recently published in the online edition of Nature. In particular, the...

A new study published in Nature shows how mitochondrial disease may be prevented NEW YORK, Dec. 19, 2012 /PRNewswire-USNewswire/ -- A joint team of scientists from The New York Stem Cell Foundation (NYSCF) Laboratory and Columbia University Medical Center (CUMC) has developed a technique that may prevent the inheritance of mitochondrial diseases in children. The study is published online today in Nature. Dieter Egli, PhD, and Daniel Paull, PhD, of the NYSCF Laboratory with Mark...

BILLERICA, Mass., Dec. 7, 2012 /PRNewswire/ -- Seahorse Bioscience, the world leader in instrumentation and assay kits for measuring cell metabolism announces travel award recipients who presented at the Asia Mito 2012 Conference, November 2-5, 2012, in Beijing. Yu Ting Wu, Ph.D., candidate at the Institute of Biochemistry and Molecular Biology, National Yang-Ming University, in Taipei, Taiwan. Poster title: Regulation of Mitochondrial FoF1ATPase Activity by Sirt3-catalyzed...

MOUNTAIN VIEW, Calif., Nov. 26, 2012 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today that it has closed a Series F Preferred Financing, raising $20M. Mitsui & Co. Global Investment, Inc. led the financing and will occupy a board of directors seat. Proceeds will be used to advance the clinical development of EPI-743. The company has recently announced the initiation of phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh...

MOUNTAIN VIEW, Calif., Nov. 13, 2012 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "A Phase 2B Randomized, Placebo-Controlled, Double-Blind Clinical Trial of EPI-743 in Children with Leigh Syndrome." Four clinical trial sites have been selected in the United States: Lucile Packard Children's Hospital, Stanford University Medical Center - Palo Alto, California; Akron Children's Hospital - Akron, Ohio; Seattle Children's Hospital -...